Vimarsana
Biggest News Aggregation in the World

Alpha Wave Global News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alpha Wave Global. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alpha Wave Global Today - Breaking & Trending Today

Oxyzo FY24 result: Oxyzo FY24 operating revenue up 59% to Rs 903 crore, net profit at Rs 290 crore - Vimarsana News

Oxyzo FY24 result: Oxyzo FY24 operating revenue up 59% to Rs 903 crore, net profit at Rs 290 crore

Oxyzo Financial Services, the lending arm of OfBusiness, reported a 59% increase in operating revenue to Rs 903 crore for FY24. The company raised $200 million at a unicorn valuation from investors like Alpha Wave Global. Ruchi Kalra leads Oxyzo, which has a net worth of Rs 2,600 crore.

HI-Bio Announces Positive Results From Phase 2 Study Of Felzartamab For Late Antibody-Mediated Rejection In Kidney Transplant Recipients - Vimarsana News

HI-Bio Announces Positive Results From Phase 2 Study Of Felzartamab For Late Antibody-Mediated Rejection In Kidney Transplant Recipients

82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n

Source: menafn.com
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences - Vimarsana News

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational...

Biogen Inc.: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences - Vimarsana News

Biogen Inc.: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational

Pine Labs Clears First Leg of Reverse Flip from S'pore - Vimarsana News

Pine Labs Clears First Leg of Reverse Flip from S'pore

Pine Labs has secured clearance from a Singapore court to merge its domestic and Singapore entities, regulatory filings show. This is a step forward for the payments company in the process of shifting domicile back to India. It now awaits a nod at this end.